Chemoprevention of cancer

Carcinogenesis

Volumn 21, Issue 3, 2000, Pages 525-530

  Sporn, Michael B ^a   Suh, Nanjoo ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; ANTIESTROGEN; ANTINEOPLASTIC AGENT; ARZOXIFENE; BETA CAROTENE; BEXAROTENE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN RECEPTOR; FENRETINIDE; OLEANOLIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RALOXIFENE; RETINOID; RETINOID X RECEPTOR; SQUALENE DERIVATIVE; TAMOXIFEN; TROGLITAZONE; UNCLASSIFIED DRUG; URSOLIC ACID DERIVATIVE;

CANCER; CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0034011263     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/21.3.525     Document Type: Review

References (47)

1. Sporn, M.B. (1996) The war on cancer. Lancet, 347, 1377-1381.
2. Kelloff, G.J. (1999) Perspectives on cancer chemoprevention research and drug development. Adv. Cancer Res., 78, 199-334.
3. Lippman, S.M., Lee, J.J. and Sabichi, A.L. (1998) Cancer chemoprevention: progress and promise. J. Natl Cancer Inst., 90, 1514-1528.
4. Chemoprevention Working Group (1999) Prevention of cancer in the next millennium: report of the Chemoprevention Working Group to the American Association for Cancer Research. Cancer Res., 59, 4743-4758.
5. Fisher, B., Costantino, J.P., Wickerham, D.L., Redmond, C.K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L. and Wolmark, N. (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J. Natl Cancer Inst., 90, 1371-1388.
6. Cummings, S.R., Eckert, S., Krueger, K.A., Grady, D., Powles, T.J., Cauley, J.A., Norton, L., Nickelsen, T., Bjarnason, N.H., Morrow, M., Lippman, M.E., Black, D., Glusman, J.E., Costa, A. and Jordan, V.C. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. J. Am. Med. Assoc., 281, 2189-2197.
7. Veronesi, U., De Palo, G., Marubini, E., Costa, A., Formelli, F., Mariani, L., Decensi, A., Camerini, T., Del Turco, M.R., Di Mauro, M.G., Muraca, M.G., Del Vecchio, M., Pinto, C., D'Aiuto, G., Boni, C., Campa, T., Magni, A., Miceli, R., Perloff, M., Malone, W.F. and Sporn, M.B. (1999) Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl Cancer Inst., 91, 1847-1856.
8. Jordan, V.C. (1976) Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinoma. Eur. J. Cancer, 12, 419-424.
9. Gottardis, M.M. and Jordan, V.C. (1987) Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res., 47, 4020-4024.
10. Anzano, M.A., Peer, C.W., Smith, J.M., Mullen, L.T., Shrader, M.W., Logsdon, D.L., Driver, C.L., Brown, C.C., Roberts, A.B. and Sporn, M.B. (1996) Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J. Natl Cancer Inst., 88, 123-125.
11. Moon, R.C., Thompson, H.J., Becci, P.J., Grubbs, C.J., Gander, R.J., Newton, D.L., Smith, J.M., Phillips, S.L., Henderson, W.R., Mullen, L.T., Brown, C.C. and Sporn, M.B. (1979) N-(4-hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res., 39, 1339-1346.
12. Sporn, M.B. and Roberts, A.B. (1984) Role of retinoids in differentiation and carcinogenesis. J. Natl Cancer Inst., 73, 1381-1387.
13. Hong, W.K. and Sporn, M.B. (1997) Recent advances in Chemoprevention of cancer. Science, 278, 1073-1077.
14. Ratko, T.A., Detrisac, C.J., Dinger, N.M., Thomas, C.F., Kelloff, G.J. and Moon, R.C. (1989) Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res., 49, 4472-4476.
15. Omenn, G.S., Goodman, G.E., Thornquist, M.D., Balmes, J., Cullen, M.R., Glass, A., Keogh, J.P., Meyskens, F.L., Valanis, B., Williams, J.H., Barnhart, S. and Hammar, S. (1996) Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med., 334, 1150-1155.
16. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med., 330, 1029-1035.
17. Hennekens, C.H., Buring, J.E., Manson, J.E., Stampfer, M., Rosner, B., Cook, N.R., Belanger, C., LaMotte, F., Gaziano, J.M., Ridker, P.M., Willett, W. and Peto, R. (1996) Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med., 334, 1145-1149.
18. Greenberg, E.R. and Sporn, M.B. (1996) Antioxidant vitamins, cancer, and cardiovascular disease. N. Engl. J. Med., 334, 1189-1190.
19. Sporn, M.B. and Roberts, A.B. (1986) Peptide growth factors and inflammation, tissue repair, and cancer. J. Clin. Invest., 78, 329-332.
20. Prescott, S.M. and White, R.L. (1996) Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. Cell, 87, 783-786.
21. Oshima, M., Dinchuk, J.E., Kargman, S.L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J.M., Evans, J.F. and Taketo, M.M. (1996) Suppression of intestinal polyposis in Apc Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803-809.
22. Kawamori, T., Rao, C.V., Seibert, K. and Reddy, B.S. (1998) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor against colon carcinogenesis. Cancer Res., 58, 409-412.
23. Tucker, O.N., Dannenberg, A.J., Yang, E.K., Zhang, F., Teng, L., Daly, J.M., Soslow, R.A., Masferrer, J.L., Woerner, B.M., Koki, A.T. and Fahey, T.J. (1999) Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res., 59, 987-990.
24. Subbaramaiah, K., Telang, N., Ramonetti, J.T., Araki, R., DeVito, B., Weksler, B.B. and Dannenberg, A.J. (1996) Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res., 56, 4424-4429.
25. Michaluart, P., Masferrer, J.L., Carothers, A.M., Subbaramaiah, K., Zweifel, B.S., Koboldt, C., Mestre, J.R., Grunberger, D., Sacks, P.G., Tanabe, T. and Dannenberg, A.J. (1999) Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation. Cancer Res., 59, 2347-2352.
26. Mohammed, S.I., Knapp, D.W., Bostwick, D.G., Foster, R.S., Khan, K.N.M., Masferrer, J.L., Woerner, B.M., Snyder, P.W. and Koki, A.T. (1999) Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res., 59, 5647-5650.
27. Kuiper, G.G., Enmark, E., Pelto-Huikko, M., Nilsson, S. and Gustafsson, J.A. (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl Acad. Sci. USA, 93, 5925-5930.
28. Lucia, M.S., Anzano, M.A., Slayter, M.V., Anver, M.R., Green, D.M., Shrader, M.W., Logsdon, D.L., Driver, C.L., Brown, C.C., Peer, C.W., Roberts, A.B. and Sporn, M.B. (1995) Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoled carcinomas of the rat seminal vesicle and prostate. Cancer Res., 55, 5621-5627.
29. Sporn, M., Suh, N., Peer, C., Williams, C., Roebuck, B., Glasebrook, A., Palkowitz, A., Bryant, H., Sato, M., Yang, N. and Fuchs-Young, R. (1997) LY353381-HCI, a new benzothiophene for chemoprevention of breast cancer. Proc. Annu. Meet. Am. Assoc. Cancer Res., 38, 527.
30. Mukherjee, R., Davies, P.J., Crombie, D.L., Bischoff, E.D., Cesario, R.M., Jow, L., Hamann, L.G., Boehm, M.F., Mondon, C.E., Nadzan, A.M., Paterniti, J.R.Jr and Heyman, R.A. (1997) Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature, 386, 407-410.
31. Mangelsdorf, D.J. and Evans, R.M. (1995) The RXR heterodimers and orphan receptors. Cell, 83, 841-850.
32. Mangelsdorf, D.J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P. and Evans, R.M. (1995) The nuclear receptor superfamily: the second decade. Cell, 83, 835-839.
33. Willy, P.J. and Mangelsdorf, D.J. (1998) Nuclear orphan receptors: the search for novel ligands and signaling pathways. Horm. Signal., 1, 307-358.
34. Gottardis, M.M., Bischoff, E.D., Shirley, M.A., Wagoner, M.A., Lamph, W.W. and Heyman, R.A. (1996) Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res., 56, 5566-5570.
35. Lehmann, J.M., Moore, L.B., Smith-Oliver, T.A., Wilkison, W.O., Willson, T.M. and Kliewer, S.A. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem., 270, 12953-12956.
36. Spiegelman, B.M. (1998) PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes, 47, 507-514.
37. Lefebvre, A.M., Chen, I., Desreumaux, P., Najib, J., Fruchart, J.C., Geboes, K., Briggs, M., Heyman, R. and Auwerx, J. (1998) Activation of the peroxisome proliferator-activated receptory promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nature Med., 4, 1053-1057.
38. Saez, E., Tontonoz, P., Nelson, M.C., Alvarez, J.G., Ming, U.T., Baird, S.M., Thomazy, V.A. and Evans, R.M. (1998) Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nature Med., 4, 1058-1061.
39. Sarraf, P., Mueller, E., Jones, D., King, F.J., DeAngelo, D.J., Partridge, J.B., Holden, S.A., Chen, L.B., Singer, S., Fletcher, C. and Spiegelman, B.M. (1998) Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nature Med., 4, 1046-1052.
40. Tontonoz, P., Singer, S., Forman, B.M., Sarraf, P., Fletcher, J.A., Fletcher, C.D., Brun, R.P., Mueller, E., Altiok, S., Oppenheim, H., Evans, R.M. and Spiegelman, B.M. (1997) Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc. Natl Acad. Sci. USA, 94, 237-241.
41. Suh, N., Wang, Y., Williams, C.R., Risingsong, R., Gilmer, T., Willson, T.M. and Sporn, M.B. (1999) A new ligand for the peroxisome proliferator activated receptor-γ (PPAR-γ), GW7845, inhibits rat mammary carcinogenesis, Cancer Res., 59, 5671-5673.
42. Tang, W. and Eisenbrand, G. (1992) Chinese Drugs of Plant Origin. Springer-Verlag, Berlin.
43. Nes, D.W. (1994) Isopentenoids and Other Natural Products: Evolution and Function. American Chemical Society, Washington, DC.
44. Huang, M.T., Ho, C.T., Wang, Z.Y., Ferraro, T., Lou, Y.R., Stauber, K., Ma.W., Georgiadis, C., Laskin, J.D. and Conney, A.H. (1994) Inhibition of skin tumorigenesis by rosemary and its constituents camesol and ursolic acid. Cancer Res., 54, 701-708.
45. Nishino, H., Nishino, A., Takayasu, J., Hasegawa, T., Iwashima, A., Hirabayashi, K., Iwata, S. and Shibata, S. (1988) Inhibition of the tumor-promoting action of 12-O-tetradecanoylphorbol-13-acetate by some oleanane-type triterpenoid compounds. Cancer Res., 48, 5210-5215.
46. Suh, N., Honda, T., Finlay, H.J., Barchowsky, A., Williams, C., Benoit, N.E., Xie, Q.W., Nathan, C., Gribble, G.W. and Sporn, M.B. (1998) Triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages. Cancer Res., 58, 717-723.
47. Suh, N., Wang, Y., Honda, T., Gribble, G.W., Dmitrovsky, E., Hickey, W.F., Maue, R.A., Place, A.E., Porter, D.M., Spinella, M.J., Williams, C.R., Wu, G., Dannenberg, A.J., Flanders, K.C., Letterio, J.J., Mangelsdorf, D.J., Nguyen, L., Porter, W.W., Ren, R.F., Roberts, A.B., Roche, N.S., Subbaramaiah, K. and Sporn, M.B. (1999) A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res., 59, 336-341.